title: [A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin for chronic hepatitis C].
abstract: A 55-year-old man with chronic hepatitis C had diarrhea with bloody stool in July, 2003 and ulcerative colitis was suspected. However, he quickly improved. He was treated with percutaneous radiofrequency ablation therapy for adenomatous hyperplasia in S5 of the liver in December, 2004. After the ablation therapy, he was treated with combination therapy of PEG-interferon alpha-2b and ribavirin for chronic hepatitis C. Because exacerbation of ulcerative colitis appeared 10 weeks after beginning of the treatment for hepatitis C, the combination therapy of PEG-interferon and ribavirin was discontinued. He was treated with mesalazine and steroid therapy for ulcerative colitis, and improved. We report the first case in Japan of the exacerbation of ulcerative colitis induced by the combination therapy of PEG-interferon and ribavirin for chronic hepatitis C.
authors.affiliation: Department of Internal Medicine, Medical Hospital, The Nippon Dental University.
authors.forename: Takuya
authors.initials: T
authors.lastname: Watanabe
authors.forename: Makoto
authors.initials: M
authors.lastname: Inoue
authors.forename: Kenu
authors.initials: K
authors.lastname: Harada
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Homma
authors.forename: Moriaki
authors.initials: M
authors.lastname: Uchida
authors.forename: Norio
authors.initials: N
authors.lastname: Ogata
authors.forename: Riko
authors.initials: R
authors.lastname: Funada
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Soga
authors.forename: Koichi
authors.initials: K
authors.lastname: Shibasaki
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D017115:Catheter Ablation; D003093:Colitis, Ulcerative / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D006498:Hepatectomy / Q000379:methods; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b